title: CaPTHUS scoring model in primary hyperparathyroidism: can it eliminate the need for ioPTH testing?
abstract: BACKGROUND
  The CaPTHUS model was reported to have a positive predictive value of 100 % to correctly predict single-gland disease in patients with primary hyperparathyroidism, thus obviating the need for intraoperative parathyroid hormone (ioPTH) testing. We sought to apply the CaPTHUS scoring model in our patient population and assess its utility in predicting long-term biochemical cure.
  
  
  METHODS
  We retrospective reviewed all parathyroidectomies for primary hyperparathyroidism performed at our university hospital from 2003 to 2012. We routinely perform ioPTH testing. Biochemical cure was defined as a normal calcium level at 6 months.
  
  
  RESULTS
  A total of 1,421 patients met the inclusion criteria: 78 % of patients had a single adenoma at the time of surgery, 98 % had a normal serum calcium at 1 week postoperatively, and 96 % had a normal serum calcium level 6 months postoperatively. Using the CaPTHUS scoring model, 307 patients (22.5 %) had a score of ≥ 3, with a positive predictive value of 91 % for single adenoma. A CaPTHUS score of ≥ 3 had a positive predictive value of 98 % for biochemical cure at 1 week as well as at 6 months.
  
  
  CONCLUSIONS
  In our population, where ioPTH testing is used routinely to guide use of bilateral exploration, patients with a preoperative CaPTHUS score of ≥ 3 had good long-term biochemical cure rates. However, the model only predicted adenoma in 91 % of cases. If minimally invasive parathyroidectomy without ioPTH testing had been done for these patients, the cure rate would have dropped from 98 % to an unacceptable 89 %. Even in these patients with high CaPTHUS scores, multigland disease is present in almost 10 %, and ioPTH testing is necessary.
authors.affiliation: Department of Surgery, Section of Endocrine Surgery, University of Wisconsin, Madison, WI, USA, elfenbein@surgery.wisc.edu.
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Elfenbein
authors.forename: Sara
authors.initials: S
authors.lastname: Weber
authors.forename: David F
authors.initials: DF
authors.lastname: Schneider
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Sippel
authors.forename: Herbert
authors.initials: H
authors.lastname: Chen
mesh_terms: D000236:Adenoma / Q000175:diagnosis*; D005500:Follow-Up Studies; D006301:Health Services Needs and Demand; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000473:pathology / Q000601:surgery*; D016343:Monitoring, Intraoperative / Q000379:methods*; D010281:Parathyroid Hormone / Q000097:blood*; D016105:Parathyroidectomy; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D010281:Parathyroid Hormone